摘要
目的 观察安罗替尼治疗难治性甲状腺癌(TC)的有效性及安全性.方法 选取河南理工大学第一附属医院 2019 年 5 月至 2023 年 5 月收治的 80 例难治性TC患者作为观察对象,根据治疗方法不同分为对照组、观察组,每组40例.对照组给予 125I粒子植入治疗,观察组给予 125I粒子植入+安罗替尼治疗.比较 2 组临床疗效、甲状腺相关抗体[降钙素(Ctn)、甲状腺球蛋白(Tg)、甲状腺球蛋白抗体(TgAb)]、癌胚抗原(CEA)、肿瘤血管标志物[血管内皮生长因子(VEGF)、低氧诱导因子-1α(HIF-1α)、血管生成素-2(Ang-2)]、视觉模拟评分(VAS)、Karnofsky功能状态评分(KPS)及不良反应情况.结果 观察组疾病控制率 88%高于对照组 68%(P＜0.05);治疗后观察组血清Ctn、Tg、TgAb、CEA、VEGF、Ang-2、HIF-1α水平低于对照组(P＜0.05);治疗后观察组KPS评分高于对照组,VAS评分低于对照组(P＜0.05);2 组不良反应发生率比较,差异无统计学意义(P＞0.05).结论 安罗替尼联合 125I粒子植入治疗难治性TC效果确切,可明显抑制患者血管形成,提高生活质量、减轻疼痛程度,且具有一定安全性.
Abstract
Objective To observe the efficacy and safety of antirotinib in the treatment of refractory thyroid cancer(TC).Methods A total of 80 patients with refractory TC treated in First Affiliated Hospital of Henan University of Science and Tecnology from May 2019 to May 2023 were selected as observation objects and were divided into the control group and the observation group according to different treatment methods,with 40 cases in each group.The control group was given 125I particle implantation treatment,and the observation group was given 125I particle implantation plus anlotinib treatment.The clinical efficacy,thyroid-related antibodies[calcitonin(Ctn),thyroglobulin(Tg),thyroglobulin antibody(TgAb)],carcinoembryonic antigen(CEA),tumor vascular markers[vascular endothelial growth factor(VEGF),hypoxic-inducing-factor-1α(HIF-1α),angiopoietin-2(Ang-2)],Visual analogue score(VAS),Karnofsky Functional status score(KPS)and adverse reactions of the two groups were compared.Results The disease control rate of 88%in the observation group was higher than that of 68%in the control group(P＜0.05).After treatment,the levels of serum Ctn,Tg,TgAb,CEA,VEGF,Ang-2 and HIF-1α in observation group were lower than those in control group(P＜0.05).After treatment,KPS score of observation group was higher than control group,VAS score was lower than control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Allotinib combined with 125I implantation in the treatment of refractory TC is effective,which can significantly inhibit the formation of blood vessels in patients,improve the quality of life,reduce the degree of pain,and has a certain safety.
NETL
NSTL
维普
万方数据